Saturday Nov. 7, 2026 Daily News #ScientificSessions26 Science & Technology Hall Map inside The evolving technology is expected to become a cornerstone of medicine and transform how numerous diseases are treated. CRISPR technologies are moving from the lab to late-stage clinical trials, potentially transforming the treatment of cardiovascular disease, rare genetic disorders and other chronic conditions. “It’s research now, but it’s not going to be research for much longer. There’s no question, these kinds of therapies are working in patients in clinical trials, and they are going to get approved,” said Kiran Musunuru, MD, PhD, MPH, ML, MRA, FAHA. “We’ll have to be a little patient and wait a few years, but they’re going to be approved, and they’re going to transform the practice of medicine.” Musunuru is among the speakers at the Saturday session “The Future Is Now: Gene Therapy for Cardiovascular Disease” who will offer insight and examples of this impact on cardiovascular health. Musunuru is the Barry J. Gertz Professor for Translational Research at the University of Pennsylvania Perelman School of Medicine in Philadelphia. CRISPR technology has evolved significantly beyond its original form, Musunuru said. Early gene editing methods focused on cutting DNA to disable harmful genes, but newer approaches enable scientists to precisely change individual DNA letters, rewrite sections of genetic code or regulate gene activity without altering the underlying sequence. CRISPR’s key advantage today is its programmability, he said. Researchers can redirect the technology to different genes by changing a short segment of guide RNA, which acts as a molecular GPS system and directs the editing machinery to a specific location within the genome. Take, for example, the gene involved in the serious and often fatal condition transthyretin amyloidosis. In one of the most advanced applications of CRISPR technology, Musunuru said, a phase 3 gene-editing trial has suggested that the therapy permanently turns off the disease-causing gene, TTR, after a single treatment. The therapy uses lipid nanoparticles to deliver CRISPR directly to liver cells and could potentially offer lifelong protection from the condition, he said. “This trial has gotten a lot of See CRISPR, page 14 Welcome to Scientific Sessions 2026! The American Heart Association’s premier scientific meeting got underway yesterday with a full day of specialized programming that brought cardiovascular professionals together to explore emerging science, exchange ideas and advance patient care. Among the opening day’s highlights were the Paul Dudley White International Lecture, delivered by Patrick W. Serruys, MD, PhD, as well as session lineups by QCOR and the Hypertrophic Cardiomyopathy Medical Society. A new addition to this year’s meeting, the Innovation Forum, put a spotlight on fresh ideas, clinical insights, research discoveries and emerging technologies with the potential to shape the future of cardiovascular medicine. Together, these programs offered a glimpse of the breadth of science, innovation and collaboration that will define the days ahead, setting the stage for a weekend dedicated to discovery, meaningful connections and improved cardiovascular health worldwide. CRISPR revolution nears mainstream cardiovascular care Kiran Musunuru, MD, PhD, MPH, ML, MRA, FAHA Endothelium emerges as central driver of disease 4 As far as the AI can see 5 The cancer and arrhythmia conundrum 6 What’s good for the heart is good for the brain 8 Inside Bioengineered blood vessels offer hope for children 13 Today at Sessions 3 UPCOMING SESSION The Future Is Now: Gene Therapy for Cardiovascular Disease 9:45–11 a.m. | Saturday, Nov. 7 S103A Distinguished Scientist pushes forward for equity 15 2026 Distinguished Scientist Awards 16
Booth #3243 Saturday, Nov. 7 | Sunday, Nov. 8 9 a.m.-4:30 p.m. (or until tests run out) Elevated uACR is an independent predictor of chronic kidney disease progression, cardiovascular events, and all-cause mortality. Fewer than 20% of U.S. adults with diabetes or hypertension receive routine uACR testing. uACR testing supported by: Paid Advertisement Testing and Awareness uACR
3 #ScientificSessions26 ScientificSessions.org Today at Sessions All sessions are located at the McCormick Place Convention Center unless otherwise noted. TCT at Sessions TCT.01 | Best of Pulmonary Embolism 2026: Who, When and How to Intervene* 9:30–10:45 a.m. | Learning Studio 5, Science & Technology Hall TCT.02 | Redefining Aortic Stenosis Treatment Paradigms* 1:30–2:45 p.m. | Learning Studio 5, Science & Technology Hall TCT.03 | Contemporary Considerations for Percutaneous Coronary Intervention* 3:15–4:30 p.m. | Learning Studio 5, Science & Technology Hall View the Industry Programming Guide for today’s events. Please see the Experience Scientific Sessions Program and the mobile app for all programming. *Not a CE accredited session. Download the Mobile Meeting Guide App Get instant access to educational sessions, faculty, industry events, exhibitors, maps and more! Late-Breaking Science and Featured Sessions Scientific Sessions 2026 Opening Session 8-8:35 a.m. | Center Stage, North Hall, Level 3 LBS.01 | The Dr. Eugene Braunwald Late-Breaking Science Session: Translating Science Into Prevention: Lessons From Landmark Trials 8:35–9:50 a.m. | Center Stage, North Hall, Level 3 Annual Dr. Nanette K. Wenger Research Goes Red® Award for Best Scientific Article on Cardiovascular Disease and Stroke in Women Lecture 9:45-11 a.m. | S100A CP.ME.12 | Bioengineering Human Tissue and the Future of Vascular Replacement in Congenital Heart Disease* 9:45–11 a.m. | Special Session, North Hall, Level 3 Distinguished Scientist Lecture 1:30-2:20 p.m. | S105D EP.ME.05 | What Comes Next for AI: Hear From the Builders of Tech’s Future 1:30–2:45 p.m. | S100A LBS.02 | Late-Breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke 1:45–2:45 p.m. | Center Stage, North Hall, Level 3 LBS.03 | Late-Breaking Science: Hot Topics in CVD Prevention 3:15–4:30 p.m. | Center Stage, North Hall, Level 3 LBS.ID.01 | LBS In-Depth 1 3:15–4:30 p.m. | S106A BH.ME.08 | The Brain Checkup: Measuring, Protecting and Preserving Your Cognitive Future* 3:15–4:30 p.m. | Special Session, North Hall, Level 3 PL.ME.03 | The Ups and Downs of Sex Hormones: Critical Windows for Cardiovascular Health in Girls and Women 3:15–4:30 p.m. | S105D HIP.19 | What Does AI Mean for the Future the Patient-Clinician Relationship 3:15–4:30 p.m. | S100A Sponsored by hsCRP FOR PROFESSIONALS SHARE your perspective and help shape future American Heart Association educational resources. GAIN new insights into the evolving role of high-sensitivity C-reactive protein (hsCRP) in cardiovascular risk assessment. TAKE A BRIEF SURVEY to help us better understand healthcare professionals’ knowledge of hsCRP. ACCESS the hsCRP toolkit for healthcare professionals today! Learn.Heart.org ©2026 American Heart Association WF1894422 10/26 Sponsored by Novo Nordisk. PAID ADVERTISEMENT WF-1894422 hsCRP Experience SS FullPg Ad-2026.indd 2 9/25/26 10:33 AM
4 SCIENTIFIC SESSIONS DAILY NEWS | Saturday, Nov. 7, 2026 Scientific consensus is growing that the endothelium plays a more active role in human health than previously understood. In fact, researchers are increasingly recognizing the vascular endothelium as one of the body’s most influential organ systems and a key driver of cardiovascular and systemic disease, said Jason Kovacic, MD, PhD, FAHA, noting that it was once regarded as little more than a passive lining of blood vessels. Kovacic explored that disconnect Friday during the session titled “The Thrombo-Inflammatory Axis: Bridging the Vessel Wall, Blood and Bedside.” The endothelium helps regulate inflammation, blood flow, thrombosis and numerous disease processes throughout the body, Kovacic said during his presentation, “The Host: Endothelial Dysfunction as the Architect of Disease.” “Data have now become compelling that the endothelium is a critical mediator of multiple diseases that include not only numerous vascular disease states, but systemic conditions and disease states as far ranging as diabetes, systemic inflammatory responses and obesity,” said Kovacic, a clinical professor of cardiology at both the Icahn School of Medicine at Mount Sinai in New York and the Victor Chang Cardiac Research Institute in Sydney, Australia. “Our understanding of the endothelium has evolved from that of a passive cell monolayer to a host and fundamental architect of disease.” Kovacic’s presentation focused on the biological mechanisms driving endothelial dysfunction. Through lab research, his team has examined endothelial-to-mesenchymal transition (EndMT), a process in which endothelial cells change in ways that contribute to vascular disease development. Researchers have identified the signaling molecule SMAD3 as a critical regulator of this process, Kovacic said. Experimental studies in cell-based and animal models showed that inhibiting SMAD3 can block EndMT and reduce neointima formation, a key factor in blood vessel narrowing after surgery. Researchers also reported improvements in vein graft patency in large-animal studies, findings that may pave the way for future therapeutic applications in vascular medicine. His team is now working to translate these discoveries into clinical practice. “The endothelium is a complex organ system. There are multiple mechanistic pathways involved that reflect the diversity of vascular and systemic disease states that the endothelium orchestrates. Accordingly, the relevant mechanistic pathways involved are as diverse as the diseases themselves,” Kovacic said. Kovacic also addressed the persistent challenge of residual cardiovascular risk. Although widely used lipid-lowering therapies, including statins and PCSK9 inhibitors, have significantly reduced cardiovascular events by lowering LDL cholesterol, Kovacic said many patients continue to experience heart attacks, strokes and other vascular complications despite optimal cholesterol management. “This residual risk is partly driven by a thrombo-inflammatory loop where chronic, low-grade inflammatory and localized pro-thrombotic signaling conspire to transform a healthy, antithrombotic luminal surface into an active participant in atherothrombosis,” Kovacic said. Beyond the cardiovascular implications, Kovacic called for a broader rethinking of endothelial Endothelium emerges as central driver of disease Jason Kovacic, MD, PhD, FAHA Functioning as a dynamic organ system, it regulates inflammation, blood flow, thrombosis and numerous disease processes throughout the body. See ENDOTHELIUM, page 18 © NewAmsterdam Pharma B.V. 2026 09/26 UM-US--0028 NewAmsterdam Pharma is committed to developing novel, nonstatin, oral therapies that will potentially reduce patients’ ASCVD risk. ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease. Reference: 1. Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2026;153:e275-e906. doi:10.1161/CIR.0000000000001412 2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153:e00-e00. doi:10.1161/CIR.0000000000001423 NewAmsterdam Pharma is dedicated to Defusing ASCVD risk IT’S TIME TO EXPECT MORE Each day >2500 US adults die of CVD,1 despite available lipid therapies Visit us at BOOTH #3102 The 2026 ACC/AHA guideline broadens the focus beyond LDL-C.2 Scan to see why looking beyond LDL-C matters. Paid Advertisement
5 #ScientificSessions26 ScientificSessions.org American Heart Association 2026 For more information, please contact AskFirst@askbio.com or scan the QR code This event is not part of the official Scientific Sessions Conference 2026 as planned by the American Heart Association Committee on Scientific Sessions Programming. Disclaimer: AB-1002 is an investigational product and is not approved by the FDA, EMA, or any other health authority. AB-1002's safety and efficacy are not established. PAID ADVERTISEMENT • Timothy Henry, MD, The Christ Hospital, Cincinnati, OH, USA • Gavin Oudit, MD, PhD, University of Alberta, Edmonton, AB, Canada • JoAnn Lindenfeld, MD, Vanderbilt University Medical Center, Nashville, TN, USA • Yuri Kim, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA Date: Sunday, November 8, 2026 Time: 11:15 a.m. – 12:00 p.m. CT Location: Learning Studio 3 Visit us at Booth 1908 Join us for a dynamic panel discussion, Q&A and lunch Gene Therapy for the Failing Heart: Early Clinical Findings with Umiposgene Parvec (AB-1002) Heart failure remains a leading cause of morbidity and mortality worldwide despite advances in pharmacologic and device-based therapies. This session will explore an investigational gene therapy being evaluated for treatment of advanced heart failure, highlighting early clinical findings with umiposgene parvec (AB-1002). The presentation will discuss the potential of gene therapy to address underlying molecular dysfunction in patients with heart failure. Learning Studio Speakers: Moderated by Roger Hajjar, MD, Mass General Brigham, Cambridge, MA, USA ABE-0217 Artificial intelligence has reached a turning point in healthcare, with increasingly sophisticated tools capable of supporting clinical decision-making, improving efficiency and helping patients manage chronic conditions. But as AI technologies advance, the question is shifting from what they can do to how effectively — and safely — they can improve patient care. “The models are now sophisticated enough to support meaningful clinical reasoning,” said Rashmee Shah, MD, a former health scientist at Meta and currently associate professor at the University of Utah in Salt Lake City. “The degree to which this technology will help people live longer, healthier lives, free of cardiovascular disease, depends on implementation, policy and regulation.” Shah will co-moderate the Saturday afternoon session “What Comes Next for AI: Hear From the Builders of Tech’s Future.” The session features Daniel Nadler, PhD, CEO of OpenEvidence, and Shiv Rao, MD, CEO and co-founder of Abridge. The two technology leaders will explore current and emerging AI applications and their potential impact on cardiology in 2027 and beyond. Although numerous companies tout novel AI tools, the tools that will make the cut and experience widespread adoption are those that solve real problems, said session comoderator Pierre Elias, MD. Healthcare AI applications primarily look to enhance diagnosis (find disease earlier, more accurately), navigate decision-making (predict options, risk, outcomes) or improve operational efficiency (automate prior authorizations, reimbursements). Vetting these technologies is critical, said Elias, an assistant professor in cardiology and biomedical informatics at Columbia University in New York and CEO and co-founder of Pathway Labs. He subscribes to a checklist of inquiries that helps “separate substance from hype”: • Identify the specific problem the tool claims it will solve. How will the outcome of this problem or process change once implemented — for better or worse? • Ask how the product was developed and tested. Was it validated in a setting or workflow similar to yours, with or without patients? What is its scope of use and its privacy and security protections? Looking beyond the company’s polished demo, Elias said peer-reviewed external validation and real-world experience from colleagues define a product’s proficiency. • Examine what could go wrong and the potential fallout. As far as the AI can see Be in the room where it happens as healthcare AI experts examine what’s coming in 2027 and beyond for cardiology. Rashmee Shah, MD Pierre Elias, MD UPCOMING SESSION What Comes Next for AI: Hear From the Builders of Tech’s Future 1:30-2:45 p.m. | Saturday, Nov. 7 S100A See AI, page 14 Don’t miss your chance to connect. View networking opportunities and events at #ScientificSessions26
6 SCIENTIFIC SESSIONS DAILY NEWS | Saturday, Nov. 7, 2026 Hypertension, Sodium and Sleep: An Integrated Approach to Cardiovascular Health Emerging research shows that blood pressure, sodium intake and sleep quality are closely interconnected. Addressing these factors together can improve patient outcomes and support comprehensive cardiovascular care. Explore educational topics, including: • How sodium intake—from both diet and prescription medications—affects blood pressure and cardiovascular risk • Practical approaches to reduce sodium exposure and enhance patient outcomes • Strategies for integrating sleep disorders screening and sleep health improvement • Cross-disciplinary insights and tools to support personalized care Expert-led podcasts, a clinical toolkit, and more, developed in collaboration with Brigham and Women's Hospital, will help you apply these strategies in practice. Scan now to find education and additional resources. © Copyright 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. WF-1852240 9/26 Jazz Pharmaceuticals, Inc. is proud to support the American Heart Association’s Hypertension, Sodium and Sleep Professional Education Initiative. Paid Advertisement A growing body of evidence is revealing important nuances for managing cancer and an arrhythmia when they coexist. Paari Dominic, MBBS, MPH, will address the research and its implications during Saturday’s “Arrhythmia Research Summit: The Latest Advances in Atrial Fibrillation.” He said it’s clear that AFib is becoming more common in cancer patients, but the reasons behind it are complex. “One (reason) is the fact that cancer patients survive longer now. Because of newer cancer therapies that are more effective, we see patients far after their cancer was diagnosed and treated,” he said. “Now you’re seeing the effects of the cancer and the cancer treatment many years later, and we’re seeing that cardiac arrhythmias are one of the effects of that cancer treatment. “The other factor is that many of the newer cancer drugs like chemotherapeutic agents are causing a lot more cardiac arrhythmias.” Dominic, who is director of electrophysiology and medical director of the electrophysiology lab at University of Iowa Health Care in Iowa City, Iowa, said ibrutinib, for example, entered the market several years ago and has been effective in treating multiple types of cancer, such as chronic lymphocytic leukemia. The downside, he said, is that the medication is also known to cause AFib. Likewise, radiation therapy has been identified as an independent risk factor for developing AFib, particularly in patients undergoing thoracic or chest-area radiation. But whether the arrhythmia is caused by medications, radiation therapy or cancer surgery, Dominic said, his research has led him to look at the common genetic and protein-based links between cancer and AFib. “Regardless of which is diagnosed first, both conditions share common phenomena, which include comorbidities, (and) gene mutations and protein disturbances that are common to both of these disease processes,” he said. “In some patients, (the common factor) causes cancer first and then causes AFib, while in others it causes AFib first and then cancer.” No matter which comes first, treatment for the AFib is going to be similar. But he cautioned that there are nuances that cardiologists need to know. “For example, when patients develop AFib, we put them on blood thinners, which are necessary to prevent stroke in AFib patients. But in a cancer patient with AFib, you have to be careful starting them on blood thinners because some of these cancers can bleed from the blood thinner and cause significant damage to these patients,” he said. “So, what we’re talking about is just how to tailor the regular treatment that you give AFib patients, based on their cancer treatment and their cancer history, and just how to make some modifications in those treatments.” Bringing to light the links between cancer and arrhythmias is fundamental for future treatment of both conditions, Dominic said. “Awareness of these two conditions existing together was not there for a very long time, and that awareness is very slowly unfolding,” he said. “But I think they are very linked diseases that we don’t always see that way. And in the future, this might be a very important area that we need to focus on.” The cancer and arrhythmia conundrum Managing overlapping cardiovascular and oncologic concerns requires a nuanced approach to patient care. Paari Dominic, MBBS, MPH UPCOMING SESSION Arrhythmia Research Summit: Latest Advances in Atrial Fibrillation 9:45–11 a.m. | Saturday, Nov. 7 N227AB
8 SCIENTIFIC SESSIONS DAILY NEWS | Saturday, Nov. 7, 2026 There’s a powerful connection between heart health and brain health. That fact could give cardiologists a compelling message in motivating patients. Successfully preserving brain function and reducing the risk of dementia is dependent on managing all aspects of heart health, including hypertension, diabetes, obesity, poor diet and other lifestyle factors, said Ronald Lazar, PhD, FAHA, FAAN. “More people are worried about dementia than a heart attack,” said Lazar, a professor of neurology and neurobiology at the University of Alabama at Birmingham Heersink School of Medicine. “We want to remind cardiologists to communicate with their patients that what they do in terms of lifestyle modifications and risk factor management benefits the brain as well. That may create a better impetus for their patients to engage in these things because they know that there’s a lot at stake.” Lazar is a speaker at the Saturday session “The Brain Checkup: Measuring, Protecting and Preserving Your Cognitive Future.” In his presentation, “Measuring Brain Health: Scores, Signals and Clinical Meaning,” Lazar will encourage cardiology colleagues to sharpen their diagnostic and communication skills to effectively measure those “target behaviors” that directly influence their patients’ brain health. His presentation will address three pillars of brain health that cardiologists should keep at the forefront: • Measuring current cognitive and functional status • Assessing the risk of future decline • Identifying actions that can help preserve cognitive function over time Lazar urges colleagues to concentrate on interventions already within their practices, such as lowering blood pressure, managing cholesterol and blood glucose levels, and promoting healthy lifestyle habits. “It’s not so much that we want cardiologists to measure what the brain is doing; it’s to measure the things that are beneficial for the brain. We’re not asking them to put a thermometer into the brain, if you will,” he said. “What we want them to do is get people to engage in the things we know are protective for the brain — things they should be doing anyway. We need to emphasize to patients that engaging in these healthy behaviors benefits the heart and the brain at the same time.” Lazar will also address the growing market of supplements, infusions and cognitive enhancement products, noting that there is limited scientific evidence that such interventions improve brain function in otherwise healthy people without specific deficiencies or medical conditions. Lifestyle management remains the most reliable strategy for long-term brain health, he said. Although digital health applications can provide reminders and educational support, Lazar said many people stop using health apps within six months. For now, he said, engagement between healthcare professionals and patients plays a vital role in encouraging lasting health behavior changes. Ultimately, the first step is education, he said: Take the time to ask your patients whether they know that risk factors for cardiovascular disease are also risk factors for brain health. “When I give talks in community settings and I ask people if they knew about the link, they usually respond, ‘I didn’t realize that,’” Lazar said. What’s good for the heart is good for the brain Educate your patients about the role of cardiovascular health strategies in reducing dementia. Ronald Lazar, PhD, FAHA, FAAN UPCOMING SESSION The Brain Checkup: Measuring, Protecting and Preserving Your Cognitive Future 3:15–4:30 p.m. | Saturday, Nov. 7 Special Session, North Hall, Level 3 Delta Dental is proud to collaborate with the American Heart Association’s Healthy Smiles, Healthy Hearts Initiative. Delta Dental is a registered trademark of Delta Dental Plans Association. Expand Your Understanding of the Dynamic Connection Between Oral and Cardiovascular Health Access our vodcast series, eModule, and other resources bringing the latest science and evidence-based strategies for you to learn about topics like patient safety, accurate blood pressure measurement, and how oral health can be associated with increased risk for cardiovascular disease and stroke risk. Multiple CE credits available, including ADA CERP. American Heart Association. Unauthorized use prohibited. WF-1928217 10/26 LEARN NOW PAID ADVERTISEMENT
10 SCIENTIFIC SESSIONS DAILY NEWS | Saturday, Nov. 7, 2026 134 Puppy Snuggles 3429 802 Eli Lilly and Company HIP 3 HIP 4 HIP 8 3414 Park Strip Sponsored by AstraZeneca 3102 NewAmsterdam Pharma Clinical Case Arena 3402 HIP 2 HIP 20 HIP 5 HIP 7 1302 Bridgebio HIP 1 HIP 11 HIP 12 HIP 13 HIP 14 HIP 15 HIP 16 HIP 17 HIP 18 HIP 19 2418 Kiniksa Pharmaceuticals HIP 9 HIPod 1 HIPod 2 HIPod 5 HIPod 6 HIPod 7 HIPod 8 HIPod 3 HIPod 4 1102 Duke Clinical Research Institute 911 Regeneron Pharmaceuticals, Inc. 711 Heartflow 2812 Edgewise Therapeutics 1217 AstraZeneca 126 Food Is Medicine Pavilion 2235 Boehringer Ingelheim Pharmaceuticals, Inc. 1019 ZOLL Medical Corporation 1908 Bayer 2218 Kardigan 2818 Alnylam Pharmaceuticals 616 Amgen 627 BMS/J&J Alliance 806 Cytokinetics 1014 117 Park Strip Sponsored by Novartis 120 Simulation Zone 1212 Bristol Myers Squibb 1602 1608 Pfizer 1612 Medtronic 1615 Novartis Pharmaceuticals Corporation 2102 Boehringer Ingelheim Pharmaceuticals, Inc. 2208 Novo Nordisk, Inc. 2223 Merck & Co., Inc. 2229 CRISPR Therapeutics 2402 Mineralys Therapuetics, Inc. 2614 Arrowhead Pharmaceuticals 2802 Ionis Pharmaceuticals, Inc. 2807 Viatris 3010 Edwards Lifesciences 3014 Idorsia Pharmaceuticals US Inc. 1206 Eli Lilly and Company 3207 American College of Cardiology 623 Milestone Pharmaceuticals 631 Bayer Heart Hub 602 Mayo Clinic Community Partners Health Innovation Pavilion Heart Theater 1 Global Quality Pavilion 13 12 Cardio Talk 1 11 Headshot Lounge Sponsored by Cedars-Sinai 10 HeartQuarters 1 Engagement Lounge Supported by Eli Lilly 2 11 4 Cardio Talk 2 Charging Lounge Sponsored by Novartis 3 Merck & Co., Inc. Sponsored by AstraZeneca Poster Attendant Booth Poster Hall Main Entrance Grand Concourse Escalator/stairs to/from Cafe 100 Publishers Row American Heart Association Scholars Posters 3702 3320 434 435 436 437 3219 3220 2630 534 537 2631 2632 3213 3214 3020 3119 3120 2607 2710 1017 3313 3314 26332634 2012 2112 3211 3215 3315 707 713 26092610 26282629 2707 2709 3007 3018 3019 3107 3118 3210 3216 3218 3310 3311 3316 3318 3319 636 736 737 607 2232 23322333 2233 2428 2429 2430 2432 2530 2531 2532 25282529 Wolters Kluwer 712 611 Science & Technology Hall Map
11 #ScientificSessions26 ScientificSessions.org 2845 B56 B57 B32 B38 B39 B3 Alnylam Pharmaceuticals B30 B31 Learning Lab: CKM Health 2446 Esperion Therapeutics 2847 3243 Testing & Awareness Lp(a), hsCRP & uACR B6 B29 B5 B50 B42 B43 B44 Learning Studio 5 B16 B17 B18 B48 B49 B47 B58 2240 B9 546 Learning Lab: Pfizer B26 B27 B28 B7 Novartis Pharmaceuticals Corporation B4 Exhibitor Lounge and Sales Office B40 B41 B8 2246 Cleveland Clinic 2645 Learning Studio 4 Learning Studio 1 B19 B2 Bristol Myers Squibb B20 B13 B14 B15 2640 CKM Health B1 Kardigan B10 B11 B12 Learning Studio 2 Learning Studio 3 2945 Mission Advancement 8 Charging Lounge Sponsored by AstraZeneca 9 7 Heart Theater 2 FAHA Lounge 5 Member Lounge Supported by Arrowhead 6 Boehringer Ingelheim Pharmaceuticals, Inc. Business Suites Escalator/stairs to/from Cafe LIB Therapeutics Bistro S31 Eli Lilly and Company Novartis Pharmaceuticals Corporation 543 544 441 442 443 28422843 30403041 B55 B33 B34 444 440 2940 2941 2942 2943 30423043 3141 3142 3143 B52 B53 B54 B51 540 B45 B46 3140 B21 B22 B23 B24 B25 B35 B36 B37 28402841 640 641 643 646 647 648 744 642 644 645 740 742 743 745 747 748 Science & Technology Hall Hours Saturday, Nov. 7 9 a.m.–4:30 p.m. Sunday, Nov. 8 9 a.m.–4:30 p.m. Monday, Nov. 9 9 a.m.–3 p.m. See more #ScientificSessions26 highlights Scientific Sessions Conference Coverage sessions.hub.heart.org Download the Mobile Meeting Guide App for interactive maps.
12 SCIENTIFIC SESSIONS DAILY NEWS | Saturday, Nov. 7, 2026 Abbott . . . . . . . . ......... HIP 8, Simulation Zone Abcentra . . . . . . . . . . . ............ HIP Pod 6, B13 ADInstruments . . . . . . . . . . . . .............. 2332 AdventHealth Research Institute . . . . ...... 2333 Agepha Pharma FZ-LLC . . . . . . . . .......... 2607 Alexion, AstraZeneca Rare Disease . . . . ..... B34 AliveCor . . . . . . . . . . . . . . . ................. HIP 1 Alnylam Pharmaceuticals . . . . . . ....... 2818, B3 Amarin Pharma, Inc. . . . . . . . . . . ........... 2112 American Academy of Periodontology Foundation . . . . . . . ....... 3218 American College of Cardiology . . . . ...... 3207 American College of Physicians/ Annals of Internal Medicine . . . . . . ...... 3314 American Heart Association AI Assessment Lab . . . . . . . . . ......... HIP 15, B28 American Association of Heart Failure Nurses . .. 3311 American Heart Association Coffee Break . . 1014 American Heart Association Nation of Lifesavers . . . . . . . . . .......... 2645 American Kidney Fund . . . . . . . . . .......... 2843 Amgen . . . . . . . . . . . . .............. 616, B19, B20 AOP Health US . . . . . . . . . . . . . .............. 736 Arrowhead Pharmaceuticals . . . . . . . ....... 2614 AskBio – a Bayer Cell & Gene Therapy Platform Company . . . . ...... B53 Association of Black Cardiologists . . . . ..... 3318 AstraZeneca . . . . . ...... 1217, B10, B25, B26, B33 Athelas . . . . . . . . . . . . . . . ................. 2530 Auxira Health . . . . . . . . . . . ............ HIP Pod 5 Banner Health . . . . . . . . . . . . .............. 2630 Bayer . . . 631, 1908, B15, B32, B51, B52, B54, B55, B56 Biobeat . . . . . . . . . . . . . . . . ................. 636 BMS/J&J Alliance . . . . . . . . ......... 627, B11, B12 Boehringer Ingelheim Pharmaceuticals, Inc. . . . .... 2102, 2235, 2240, . . . . . . . . . . . . . .............. B17, B18, B47, B48 Boston Scientific . . . . . . . . .......... Simulation Zone Braveheart Bio . . . . . . . . . . ............ 3019, B36 Bridgebio . . . . . . . . ......... 1302, B21, B22, B38 Bristol Myers Squibb . . . . . . . . . ......... 1212, B2 Cambrian Health . . . . . . . . . . . . . . . . . . . . . . . 2634 Cardio Flow Design Inc. . . . . . . . . ......... HIP 14 Cardiosense . . . . . . . . . . . . . . ............... 748 Caristo Diagnostics . . . . . . . . . . . ............ 607 CB Innovations . . . . . . . . . . . . . .............. 611 CKM Health . . . ..... 2640, Learning Lab 2- 2945 Cleerly Inc. . . . . . . . . . . . . ............. HIP Pod 8 Cleveland Clinic . . . . . . . . . . . . ............. 2246 Corcept Therapeutics . . . . . . . . . . ........... 707 CRISPR Therapeutics . . . . . . . . . . ........... 2229 Cytokinetics . . . . . . . . . . . . . . ............... 806 DiaPharma Group . . . . . . . . . . . ............ 3118 Duke Clinical Research Institute . . . . . ...... 1102 ECD Global Alliance . . . . . . . . . . ........... 3316 Echo IQ . . . . . . . . . . . ............. HIP Pod 1, B35 Edgewise Therapeutics . . . . . ...... 2812, B57, B58 Edwards Lifesciences . . . . . . . . . . .......... 3010 Eli Lilly and Company . . . . . ...... 802, 1206, S31 Elucid . . . . . . . . . . . . . . . . . ................. 3018 Endless Dx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437 Erlanger Health . . . . . . . . . . . . .............. 744 Esperion Therapeutics . . . . . . . ........ 2446, B14 Exhibitor Lounge and Sales Office . . . . ....... B4 Fair Medical Hire . . . . . . . . . . . ............ HIP 17 Family Heart Foundation . . . . . . . . ......... 2428 FDA - Bad Ad Program . . . . . . . . . .......... 3219 Food Is Medicine . . . . . . . . . . . . ............. 126 Foresee Pharmaceuticals . . . . . . . . . ......... 713 Foundation for Sarcoidosis Research . . . .... 3220 Frontiers Media SA . . . . . . . . . . . . . . . . . . . . . . 2609 FUJIFILM VisualSonics . . . . . . . . . . .......... 2012 Genentech . . . . . . . . . . . . ............ 2432, B27 Global Learning Collaborative . . . . . . ....... 642 Google . . . . . . . . . . . . . . . ................. HIP 2 HealthSeers, Inc. . . . . . . . . . . . ............ HIP 11 Heart Lung AI . . . . . . . . . . . . . . .............. 641 Heartflow, Inc. . . . . 711, 1017, B45, Simulation Zone Hypertrophic Cardiomyopathy Association . 2707 Idorsia Pharmaceuticals US Inc. . . . . . ...... 3014 Imbria Pharmaceuticals . . . . . . . . . ......... 3119 ImpediMed . . . . . . . . . . . . . . ................ 737 Indiana University School of Nursing . . . .... 3313 Intellia Therapeutics . . . . . . . ....... 2233, B6, B8 InterAmerican Heart Foundation . . . . . ..... 3214 Intermountain Health . . . . . . . . . . ........... 648 Ionis Pharmaceuticals, Inc. . . . ... 2802, B41, B42 JAMA Network . . . . . . . . . . . . . .............. 537 Jiangsu Tingsn Technology Co., Ltd. . . . .... HIP 9 Johnson & Johnson Medtech . . . . ....Simulation Zone Kaneka - LIPOSORBER . . . . . . . . . . .......... 712 Kardigan . . . . . . . . . . . . . . .............. 2218, B1 Kiniksa Medical Pharmaceuticals . . . . . ...... B23 Kiniksa Pharmaceuticals . . . . . . . . ......... 2418 Lexeo Therapeutics, Inc. . . . . . . . . .......... 2430 LIB Therapeutics . . . . . . . . . . . . ............. 540 MannKind . . . . . . . . . . . . . . . ............... 3210 Mayo Clinic . . . . . . . . . . . . .............. 602, B9 mdgroup . . . . . . . . . . . . . . . ................ 2529 MDisrupt . . . . . . . . . . . . . . ................ HIP 13 Med Learning Group . . . . . . . . . . ............ 434 Mediwhale . . . . . . . . . . . . . . ................ 743 Medsignals . . . . . . . . . . . . . . ............... 2531 Medtronic . . . . . . . ........ 1612, Simulation Zone Mentice, Inc. . . . . . . . . .......... Simulation Zone Merck & Co., Inc. . . .... 1602, 2223, B40, B49, B50 Metabolic Endocrine Education Foundation . .. 3215 MetwareBio . . . . . . . . . . . . . ............... 2709 Milestone Pharmaceuticals . . . . . . . ......... 623 Mineralys Therapeutics, Inc. . . . . ...... 2402, B31 Modivcare . . . . . . . . . . . . . . ................ HIP 7 New York Life Insurance . . . . . . . . .......... 2633 NewAmsterdam Pharma . . . . . . ....... 3102, B24 nference . . . . . . . . . . . . . . . ................ 2628 Nightingale Health . . . . . . . . . . . ............ 544 Noah Labs . . . . . . . . . . . . ............. HIP Pod 3 Nova in Silico . . . . . . . . . . . . . . ............... 644 Novartis Pharmaceuticals Corporation . . . . . . . ........ 1615, B7, B29, B30 Novo Nordisk, Inc. . . . . . . . . . ........... 2208, B5 OBiO TECH, INC . . . . . . . . . . . . ............. 2528 Omron Healthcare, Inc . . . . . . . . . .......... 2232 Park Strip: AstraZeneca . . . . . . . . . ......... 3414 Park Strip: Novartis . . . . . . . . . . . ............ 117 Penumbra, Inc. . . . . . . . ......... Simulation Zone Pfizer . . . . . . . . . . . . 740, 1608, Learning Lab 1-546 PharmaSmart International . . . . . . ........ HIP 4 Photon Medics . . . . . . . . . . . . .............. 3020 Poster Attendant Booth . . . . . . . . .......... 3429 Propria LLC . . . . . . . . . . . . . . ............... 2429 Puppy Snuggles . . . . . . . . . . . . . ............. 134 QT Medical Inc. . . . . . . . . . . . . ............. 2710 Radcliffe Cardiology . . . . . . . . . . ........... 3107 Regeneron Medical Affairs . . . . . . ....... 911, B39 Research Diets, Inc. . . . . . . . . . . . ........... 2610 Sensor Bio . . . . . . . . . . . . .............. HIP Pod 4 Shaia Medical Heritage Apparel . . . . . ...... 2629 Sharecare . . . . . . . . . . . . . . ................ HIP 5 SleepImage . . . . . . . . . . . . . . ............... 747 SLIIIP Medical Group PA . . . . . . . . ......... HIP 12 StopAfib.org . . . . . . . . . . . . . ............... 3216 SurgeonsLab, Inc. . . . . . . ........ Simulation Zone Surgical Science, Inc . . . . . ...... Simulation Zone Sutter Health - Physician & APC Recruitment . .. 640 Syneos Health . . . . . . . . . . . . .............. 2532 Tabia Health . . . . . . . . . . . . .............. HIP Pod 2 Testing & Awareness: Lp(a), hsCRP & uACR . . . . . . . . .......... 3243 The Japanese Circulation Society . . . . . . . . . . 742 TIMI Study Group . . . . . . . . . . . ............ 3007 Topcon Healthcare . . . . . . . . . . .......... HIP 20 Ultromics . . . . . . . . . . . . . . . ................. 745 United Therapeutics . . . . . . . . . . ........... 3211 VHOS-ai srl . . . . . . . . . . . . . . ............... HIP 3 Viatris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2807, B46 Viking Therapeutics . . . . . . . . .......... 3310, B37 Wolters Kluwer . . . . . . . . . . . . . .............. 534 Women As One . . . . . . . . . . . . ............. 3213 WuXi AppTec . . . . . . . . . . . . . ............... 543 Xenter . . . . . . . . . . . . . . . ................. HIP 16 Zelery Med-Corporation . . . . . . ....... HIP Pod 7 ZOLL Medical Corporation . . . . . . . . ........ 1019 2026 Exhibitors Welcome First-Time Exhibitors to Scientific Sessions! These companies are highlighted in red. Located in the Heart Hub CardioTalks . . . . . . . . . . . . . . . ............... 4, 11 Charging Lounges . . . . . . . . . . . . . .............. 3, 9 (Sponsored by Novartis and AstraZeneca) Engagement Lounge. . . . . . . . . . . . ............. 2 (Supported by Eli Lilly) FAHA Lounge. . . . . . . . . . . . . . . . ................ 5 Global Quality Showcase. . . . . . . . . . .......... 12 Headshot Lounge. . . . . . . . . . . . . . . . ............... 10 (Sponsored by Cedars-Sinai) Heart Theaters . . . . . . . . . . . . . .............. 7, 13 HeartQuarters. . . . . . . . . . . . . . . ................ 1 Member Lounge. . . . . . . . . . . . . . ............... 6 (Supported by Arrowhead) Mission Advancement. . . . . . . . . . . . ............ 8 Health Innovation Pavilion, Booth 100 | Simulation Zone, Booth 120 HIP = Health Innovation Pavilion
13 #ScientificSessions26 ScientificSessions.org Connecting at the Point of Care: Leveraging Industry Innovation with Integrated Cardiovascular-Kidney-Metabolic Care Delivery The American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative is made possible by Founding Sponsors Novo Nordisk and Boehringer Ingelheim, Supporting Sponsors Novartis Pharmaceuticals Corporation and Bayer, and Champion Sponsor DaVita. PAID ADVERTISEMENT © 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. 9/26 WF1772201 In this exclusive discussion, healthcare and industry leaders will explore why gaps persist between evidence and real-world outcomes, how access barriers limit the impact of innovation, and what deliberate partnerships are needed to connect therapeutics with the care networks serving patients with CKM conditions. SATURDAY, NOV. 7 | 2pm – 2:45pm CST, INDUSTRY MEETING ROOM *Attendance is limited to 100 participants. Arrive early and secure your seat for this must-attend conversation. For more opportunities to engage with CKM Health resources and education: Heart.org/CKMHProfessional VISIT BOOTH #2640 Breakthrough science doesn’t automatically translate into better outcomes WF-1772201 CKM Scientific Sessions Print Ads-_2026-5.indd 3 9/22/26 9:37 AM Children born with complex congenital heart defects have new hope, thanks to the latest generation of autologous, tissue-engineered blood vessels. Advances in the field could potentially reduce the need for repeated surgeries and change the future of pediatric cardiac care, said Christopher Breuer, MD, a speaker Saturday at the session “Bioengineering Human Tissue and the Future of Vascular Replacement in Congenital Heart Disease.” During his presentation, “Lessons in Tissue-Engineered Vascular Graft Remodeling in Children With CHD,” Breuer will detail how these advances are bringing researchers closer to creating critical engineered tissues that can grow and remodel with young heart patients. “The surgical repair of most complex cardiac anomalies requires the use of prosthetic biomaterials in the form of vascular grafts, heart patches or replacement valves. Complications associated with the use of these biomaterials are a significant source of morbidity and mortality in this patient population,” said Breuer, the director of the Center for Regenerative Medicine at Nationwide Children’s Hospital in Columbus, Ohio. “Exclusive use of autologous tissue avoids these complications but is frequently not possible due to the extent of the underlying heart defect. “Tissue engineering provides a method for creating autologous neotissue, which can be used to repair or replace tissues that are diseased, damaged or congenitally absent.” Engineered tissues integrate naturally with the body, Breuer said. However, the technology faces scientific and regulatory challenges. To illustrate these challenges, Breuer will focus on a tissue-engineered vascular graft designed for congenital heart surgery, the hurdles of translating the technology from bench to bedside, and strategies to overcome or avoid them. One of the biggest challenges facing pediatric heart patients, he said, is somatic overgrowth, where a child physically outgrows an implanted graft or valve. Because current prosthetic devices can’t grow, Breuer said patients need additional interventions, including surgical replacement or stent expansions, as they age. These “upsizing” procedures can threaten a child’s health and can place a substantial burden on patients and families. “Surgeons have had to develop strategies to delay surgery or use oversized devices to avoid somatic overgrowth. These strategies are associated with their own risks,” Breuer said. “The development of vascular grafts or replacement heart valves with growth capacity could avoid these complications and improve outcomes.” The key advantage of these autologous grafts, however, is their ability to integrate into the body. “By creating neotissue from a patient’s own cells, we can avoid the risk of rejection. Additionally, the autologous neotissue can use the body’s own mechanisms to repair, remodel and grow, thus improving durability and performance,” he said. Breuer said the advancement of the technology depends on close collaboration among scientists, clinicians and regulators to ensure the safe, efficient development of regenerative medicine technologies. Several factors, he said, can facilitate that progress: • Understanding the cellular and molecular mechanisms underlying neotissue formation. • Developing metrics specific to tissue-engineered devices to describe differences in graft performance. • And investigating how the new devices affect late-term complications in cases where current vascular grafts and replacement valves are particularly problematic. Bioengineered blood vessels offer hope for children Advances in tissue-engineered vascular grafts offer possibilities for treating congenital heart defects. UPCOMING SESSION Bioengineering Human Tissue and the Future of Vascular Replacement in Congenital Heart Disease 9:45-11 a.m. | Saturday, Nov. 7 Special Session‚ North Hall‚ Level 3 Christopher Breuer, MD Photo credit: Nationwide Children’s Hospital
14 SCIENTIFIC SESSIONS DAILY NEWS | Saturday, Nov. 7, 2026 Learn the latest on HFmrEF/HFpEF in the American Heart Association’s podcast series and eModule. • Diagnosis • Heart Failure Phenotypes • Connection to Cardio-Kidney-Metabolic Syndrome • Medical and Device Therapies • Practical Application and Access to Treatment Funding for this American Heart Association educational program is provided by Bayer. Learn Now HFmrEF/HFpEF: From Symptoms to Solutions © Copyright 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. WF-1932190 9/26 PAID ADVERTISEMENT American Heart Association® Lifelong LearningTM interest recently because now there are therapies for this disease for the first time — in just the past 10 to 15 years. Before, it was untreatable, and it was uniformly fatal. But now we have treatments that don’t just improve the disease but improve life expectancy,” Musunuru said. “The premise is that when you turn off a gene at the DNA level, it’s permanently off; it’s off forever. So, if you receive this treatment once, you are protected for the rest of your life.” The same platform has also been adapted to treat hereditary angioedema, a disease characterized by dangerous swelling attacks. By altering the genetic “GPS” component of the therapy, researchers redirected CRISPR to KLKB1, the gene responsible for the condition. According to Musunuru, clinical trial results have shown the treatment can effectively eliminate disease episodes, offering a potential one-and-done therapy for patients who currently live with ongoing risk. One of the most promising cardiovascular applications of today’s CRISPR technology is treating high cholesterol and atherosclerotic cardiovascular disease, Musunuru said. Clinical trials targeting PCSK9 and ANGPTL3, genes that influence cholesterol levels, show promise so far. For example, he said, early data show that a single treatment targeting PCSK9 can reduce LDL cholesterol by approximately 60% with effects that appear durable over time. Although the focus of Musunuru’s presentation will be on cardiovascular applications, he said the technology has the potential to revolutionize the care of other chronic diseases, including the rare inherited disorder phenylketonuria and fatty liver disease, and change the way we look at preventive healthcare in younger people. In the future, healthy people at elevated cardiovascular risk could potentially receive a one-time therapy that provides decades of protection against heart attacks and strokes, he said. “By being able to change a few letters, this technology allows us to think about drug development in a very different way. Everyone in the room should get ready for the day they’ll be prescribing these therapies. And they should have some understanding of how it works and what it does,” Musunuru said. “It will be like antibiotics. It will be so routine that it’s just part of the standard of care. It’s going to be a mainstay of medicine.” CRISPR continued from page 1 How widespread are the consequences, and who is responsible for monitoring or correcting errors? • Start using it and measure the outcomes. Then, answer the ultimate query: Does it solve the problem in a way that benefits patients and the practice? “The question is not simply, ‘How smart is the AI?’ It is, ‘Does it help deliver better care with an acceptable burden and risk?’” he said. For cardiology in particular, Shah said AI’s biggest impact is likely to occur between visits, such as in monitoring patient progress and coordinating care. “Much of cardiology is chronic disease management, including hypertension, heart failure, lipid management and anticoagulation,” she said. “Hopefully, AI will make it easier for the key stakeholder (the patient) to manage their health with less friction.” Shah predicted the technologies that will scale earliest and be implemented most are those that ease the task load of clinicians or patients while keeping them in the loop, requiring final sign-off or both. “AI-assisted front doors to healthcare will also see broad adoption. These include agents that help patients with scheduling, refills and prior authorizations — the administrative work that consumes significant time for clinicians and patients. Eventually, agent-to-agent workflows will be mainstream,” Shah said. Meanwhile, fully autonomous applications face an immeasurable obstacle course in regulation and accountability, she said. The session panelists, Nadler and Rao, will address these challenges, along with other hurdles such as safety and scalability. AI continued from page 5
15 #ScientificSessions26 ScientificSessions.org Find out how Lp(a) impacts your patients Novartis Pharmaceuticals Corporation supports Driving Awareness and Shared Decision-Making Around Lp(a) 2026. © 2026 American Heart Association, Inc., 501(c)(3) not-for-profit. All rights reserved. Lifelong Learning is a trademark of the AHA. Unauthorized use prohibited. WF650001 10/26 Paid Advertisement Lp(a) Toolkit for Healthcare Professionals High levels of plasma lipoprotein(a) (Lp(a)) are independently associated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of myocardial infarction, peripheral arterial disease, and stroke. Learn more in this toolkit for healthcare professionals. Lp(a): A Survey for Healthcare Professionals We invite you to take part in a brief survey designed to assess your knowledge of Lp(a) and help us understand your practice. Your responses will help the American Heart Association shape future educational activities that drive further awareness of Lp(a) screening and overall ASCVD risk management. Distinguished Scientist pushes forward for equity Veteran epidemiologist calls for a focus on prevention, equitable health and responsible AI. After three decades at the forefront of atrial fibrillation research, Emelia J. Benjamin, MD, ScM, FAHA, is looking beyond her accomplishments to the challenges that will define the next generation of cardiovascular science. In her Distinguished Scientist Lecture, “30 Years of Epidemiologic Discovery: Challenging the Next Generation to Realize Equitable AFib Prevention,” Benjamin will call for action dedicated to atrial fibrillation primary and secondary prevention, equitable health and emerging technologies. “We cannot achieve major advances in the health of people at risk and with AFib unless we intensify our commitment to addressing inequities in atrial fibrillation prevention to reduce the onset and complications in AFib,” she said. Benjamin will also trace AFib research from foundational epidemiology and risk factor identification to today’s increasingly sophisticated approaches incorporating imaging, genomics, artificial intelligence and precision medicine. “I am not merely presenting the greatest hits of my research. I am capturing where the field has been and is going. It involves the work of many, and I have been blessed to have been able to play a part,” said Benjamin, who is a professor of epidemiology at Boston University School of Public Health. She is also interim associate dean for faculty development and the Jay and Louise Coffman Professor in Vascular Medicine at Boston University Chobanian & Avedisian School of Medicine in Massachusetts. Benjamin points to AI as a recent major potential advancement but cautions it still requires scrutiny. “There is promise, and there are perils associated with AI in advancing AFib prediction, prevention (and) management as well as the prevention of complications,” she said. The AFib arena has traditionally focused on treating established disease through anticoagulants and rate or rhythm control strategies, she said. This has resulted in primary and secondary prevention research lagging behind coronary heart disease research. She encourages the next generation of researchers and clinicians to accelerate prevention-focused approaches while addressing longstanding inequities in diagnosis, management and outcomes that are experienced by multiple demographic groups (based on factors such as education, race and ethnicity, and rural communities). Despite challenges, Benjamin sees reasons to be optimistic. Recent European and U.S. AFib guidelines now place greater emphasis on prevention strategies, she said, with U.S. guidelines and performance and quality statements highlighting the importance of measuring and ensuring equitable care for patients. These developments signal a promising shift toward a more proactive and inclusive approach to AFib management, she said. Reflecting on her own career, Benjamin is grateful for her collaborations with trusted organizations such as the National Institutes of Health and the American Heart Association on scientific statements and research priorities. But mentorship has meant the most to her. “My most substantive career achievements include founding faculty development at the Boston University Medical Campus, and mentoring, sponsoring and coaching my many early career colleagues who will continue to advance public health and health sciences decades after I retire,” she said. Benjamin said she will end her talk by sharing some lessons from her journey. As in most careers, she encountered hurdles. Yet she credits resilience, viewing obstacles as opportunities and investing in future generations as essential to long-term success and professional fulfillment. Emelia J. Benjamin, MD, ScM, FAHA
RkJQdWJsaXNoZXIy MjI2NjI=